Home » Topics » BioWorld Science

BioWorld Science
RSS

Epstein-Barr virus vaccine enters phase I

Dec. 8, 1997

Antiinflammatory and COX-2-inhibitory effects reported for rutaecarpine

Dec. 8, 1997

HMR begins phase II trial with GA-EPO

Dec. 8, 1997

IntraBiotics signs manufacturing and supply agreement for IB-367

Dec. 8, 1997

Zeneca selects EGFR-TK inhibitor for clinical evaluation

Dec. 8, 1997

IL-12 for treatment of malignant tumors

Dec. 8, 1997

Byk Gulden presents new PDE IV inhibitors

Dec. 8, 1997

Egis prepares new AMPA receptor antagonists

Dec. 8, 1997

Analgesics under evaluation at Ortho

Dec. 8, 1997

Structurally distinct class of 5-HT1B antagonists prepared at SmithKline Beecham

Dec. 8, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 4, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...